9192570

Cases: 4
Active: 1; 3 closed
Filed: 2016–2019
Top venue: D. New Jersey; 2 cases

Adapt Pharma Operations Limited et al. v. Teva Pharmaceuticals USA, Inc. et al.

judgment (invalidity); affirmed on appeal

Docket:: 2:16-cv-07721 (JLL)(JAD); 2:17-cv-00864; 2:17-cv-02877; 2:17-cv-05100; 2:18-cv-09880
Court:: U.S. District Court for the District of New Jersey
Filed:: 2016-11-26
Terminated:: 2020-06-26

Patents:9192570 9468747 9561177 9629965 9775838 10085937

π Adapt Pharma Operations Limited π Adapt Pharma Inc.π Adapt Pharma Limited π Opiant Pharmaceuticals, Inc.Δ Teva Pharmaceuticals USA, Inc.Δ Teva Pharmaceuticals Industries, Ltd.

Adapt and Opiant sued Teva in D.N.J. asserting NARCAN naloxone nasal spray patents. The district court found the asserted patents invalid for obviousness on June 5, 2020, with judgment entered June 26, 2020; the Federal Circuit affirmed on Feb. 10, 2022. The '570 patent was not asserted but was cited as prior art (Wyse). Consolidated/related docket numbers included 2:17-cv-00864, 2:17-cv-02877, 2:17-cv-05100, 2:18-cv-09880; related Perrigo action 2:18-cv-15287.

Adapt Pharma Operations Limited et al. v. Perrigo UK FINCO Limited Partnership

related action

Docket:: 2:18-cv-15287
Court:: U.S. District Court for the District of New Jersey

Patents:9192570 9468747 9561177 9629965 9775838 10085937

π Adapt Pharma Operations Limited π Adapt Pharma Inc.π Adapt Pharma Limited π Opiant Pharmaceuticals, Inc.Δ Perrigo UK FINCO Limited Partnership

Related Perrigo action in the D.N.J. NARCAN litigation; Perrigo UK FINCO Limited Partnership named as defendant. The '570 patent was not asserted; it was prior art (Wyse) in the related litigation.

Nalox-1 Pharmaceuticals LLC v. Opiant Pharmaceuticals, Inc.

IPR petitions filed

Docket:: IPR2019-00685; IPR2019-00688; IPR2019-00691; IPR2019-00694
Court:: Patent Trial and Appeal Board
Filed:: 2019-02-19

Patents:9192570 9468747 9561177 9629965 9775838

π Nalox-1 Pharmaceuticals LLC Δ Opiant Pharmaceuticals, Inc.

Nalox-1 filed multiple IPR petitions against Opiant challenging U.S. 9,468,747; 9,561,177; 9,629,965; 9,775,838. The '570 patent was not challenged; it was cited as prior art (Wyse).

AntiOp, Inc. v. Reckitt Benckiser Pharmaceuticals, Inc.

decided at Rule 12(b)(6)/forum-selection stage

Patents:9192570

π AntiOp, Inc.Δ Reckitt Benckiser Pharmaceuticals, Inc.

Breach-of-contract action in which AntiOp alleged entitlement to a $3,000,000 milestone payment upon issuance of its '570 patent. The court addressed which forum governed under the agreement's forum-selection clause (S.D.N.Y. was designated). Not a patent infringement suit.